Bennett MI Rayment C Hjermstad M Aass N Caraceni A Kaasa S.

Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review.

Pain. 153: 359-365

An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms.

Clin J Pain. 18: 343-349Mercadante S Gebbia V David F Aielli F Verna L Casuccio A et al.

Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients.

J Pain. 10: 594-600Jensen MP Chodroff MJ Dworkin RH.

The impact of neuropathic pain on health-related quality of life: review and implications.

Neurology. 68: 1178-1182Finnerup NB Sindrup SH Jensen TS.

The evidence for pharmacological treatment of neuropathic pain.

Pain. 150: 573-581Morrone LA Scuteri D Rombola L Mizoguchi H Bagetta G.

Opioids Resistance in Chronic Pain Management.

Curr Neuropharmacol. 15: 444-456Chaparro LE Wiffen PJ Moore RA Gilron I.

Combination pharmacotherapy for the treatment of neuropathic pain in adults.

Cochrane Database Syst Rev. ()

IASP. Neuropathic pain, prevalence, entities and clinical impact. 2017.

World Health Organization guidelines for cancer pain: a reappraisal.

Ann Oncol. 16 ()Meuser T Pietruck C Radbruch L Stute P Lehmann KA Grond S.

Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology.

Pain. 93: 247-257Breivik H Cherny N Collett B de Conno F Filbet M Foubert AJ et al.

Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes.

Ann Oncol. 20: 1420-1433

Practical issues when using neuraxial infusion.

Oncology (Williston Park). 13 (): 37-44Piano V Verhagen S Schalkwijk A Burgers J Kress H Treede RD et al.

Diagnosing neuropathic pain in patients with cancer: comparative analysis of recommendations in national guidelines from European countries.

Pain Pract. 13: 433-439

Interventional therapies for the management of cancer pain.

J Support Oncol. 8: 52-59

EMA. Vectibix: Summary of Product Characteristics https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf2020

Lacouture ME Anadkat MJ Bensadoun RJ Bryce J Chan A Epstein JB et al.

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Support Care Cancer. 19: 1079-1095

Cetuximab alleviates neuropathic pain despite tumour progression.

BMJ Case Rep. ()Kersten C Cameron M Mjaaland S.

Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain—A case series.

Scandinavian Journal of Pain. 4 (): 3-7

A new treatment principle for neuropathic pain? Approved oncologic drugs: Epidermal growth factor receptor (EGFR) inhibitors dramatically relieve severe neuropathic pain in a case series.

Scand J Pain. 4: 1-2Kersten C Cameron MG Laird B Mjaland S.

Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain.

Br J Anaesth. 115: 761-767Kersten C Cameron MG Bailey AG Fallon MT Laird BJ Paterson V et al.

Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial.

Pain Med. Mitchell R Mikolajczak M Kersten C Fleetwood-Walker S.

ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain.

Neurobiol Dis. 142104961Mariani P Blumberg J Landau A Lebrun-Jezekova D Botton E Beatrix O et al.

Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.

J Clin Oncol. 30: 4337-4343Bellavance EC Alexander Jr., HR

Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction.

J Clin Oncol. 30: 4290-4291Hui D Glitza I Chisholm G Yennu S Bruera E.

Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials.

Cancer. 119: 1098-1105Dworkin RH Turk DC Wyrwich KW Beaton D Cleeland CS Farrar JT et al.

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.

J Pain. 9: 105-121Caraceni A Cherny N Fainsinger R Kaasa S Poulain P Radbruch L et al.

Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care.

J Pain Symptom Manage. 23: 239-255

Guidance for Industry Analgesic Indications: Developing Drug and Biological Products (draft).

Guideline on the clinical development of medicinal products intended for the treatment of pain.

Melosky B Leighl NB Rothenstein J Sangha R Stewart D Papp K.

Management of egfr tki-induced dermatologic adverse events.

Curr Oncol. 22: 123-132Zhi WI Gentile D Diller M Kinney A Bao T Master V et al.

Patient-Reported Outcomes of Pain and Related Symptoms in Integrative Oncology Practice and Clinical Research: Evidence and Recommendations.

Oncology (Williston Park). 35: 35-41

Improving the Evidence Base in Palliative Care to Inform Practice and Policy: Thinking Outside the Box.

J Pain Symptom Manage. Chen EK Riffin C Reid MC Adelman R Warmington M Mehta SS et al.

Why is high-quality research on palliative care so hard to do? Barriers to improved research from a survey of palliative care researchers.

J Palliat Med. 17: 782-787Dworkin RH Turk DC Peirce-Sandner S Baron R Bellamy N Burke LB et al.

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations.

Pain. 149: 177-193Verhagen CC Niezink AG Engels YY Hekster YY Doornebal JJ Vissers KC.

Off-label use of drugs in pain medicine and palliative care: an algorithm for the assessment of its safe and legal prescription.

Pain Pract. 8: 157-163

Unlicensed uses for medication in a palliative care unit.

Palliat Med. 13: 145-152

Use of unlicensed medication in palliative medicine.

Palliat Med. 13: 446Klepstad P Loge JH Borchgrevink PC Mendoza TR Cleeland CS Kaasa S.

The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients.

J Pain Symptom Manage. 24: 517-525Hagen NA Stiles C Nekolaichuk C Biondo P Carlson LE Fisher K et al.

The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews.

J Pain Symptom Manage. 35: 136-152Freynhagen R Baron R Gockel U Tolle TR.

painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain.

Curr Med Res Opin. 22: 1911-1920Tan JK Tang J Fung K Gupta AK Thomas DR Sapra S et al.

Development and validation of a comprehensive acne severity scale.

J Cutan Med Surg. 11: 211-216Fallon MT Storey DJ Krishan A Weir CJ Mitchell R Fleetwood-Walker SM et al.

Cancer treatment-related neuropathic pain: proof of concept study with menthol–a TRPM8 agonist.

Support Care Cancer. 23: 2769-2777Dworkin RH Turk DC Farrar JT Haythornthwaite JA Jensen MP Katz NP et al.

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.

Pain. 113: 9-19